BioLineRx Ltd. BLRX
1.77 USD -0.10 (-5.45%)
At closeNov 5, 2026, 4:00 PM EST
1.69 -0.08 -4.41%
After hours · Nov 5, 4:00 PM ET
1.70 Day range 1.92
1.77 52-week range 3.78
- YTD
- -36.17%
- 1 year
- -49.20%
- Market cap
- 8.80M
- Revenue (ttm)
- 17.05M
- Profit margin
- -176.67%
- Shares out
- 84.11M
- Forward P/E
- -1.06
- YTD return
- -36.17%
- 1-year return
- -49.20%
- Volume
- 15.16K
- Avg volume
- 17.14K
- Open
- 1.92
- Previous close
- 1.87
- Day's range
- 1.70 – 1.92
- 52-week range
- 1.77 – 3.78
- Beta
- 0.87
- Price target
- 4.57 (+158.3%)
5D -0.22 (-11.06%)
Key statistics
- Enterprise value
- 316.99M
- PEG ratio
- 0.00
- Price / sales
- 1.34
- Price / book
- 19.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.81M
- Total cash
- 40.06M
- Total debt
- 31.25M
- Return on equity
- -171.94%
- Short % of float
- 1.33%
- 50-day average
- 0.3624
- 200-day average
- 0.62615
Analyst view
Price target (mean) 4.57 +158.3% upside
Now 1.77
- Target (low)
- 2.00
- Target (mean)
- 4.57
- Target (high)
- 9.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
BLRX Revenue — quarterly 294.00K
BLRX Net income — quarterly -4.34M
BLRX EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 25, 2024 | Sep 1, 2024 | -0.08 | -0.07 | +0.01 | +12.50% |
| Aug 15, 2024 | Jun 1, 2024 | -0.08 | 0.01 | +0.09 | +112.50% |
| May 28, 2024 | Mar 1, 2024 | -0.29 | -0.01 | +0.28 | +96.55% |
| Mar 26, 2024 | Dec 1, 2023 | -0.22 | -0.15 | +0.07 | +31.82% |
| Nov 20, 2023 | Sep 1, 2023 | -0.18 | -0.30 | -0.12 | -66.67% |
| Aug 30, 2023 | Jun 1, 2023 | -0.16 | -0.30 | -0.14 | -87.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- biolinerx.com
News
BioLineRx And Hemispherian Present Data At ESMO 2026 Demonstrating Synergy Between GLIX1 And Multiple PARPi In Homologous Recombination-Proficient Ovarian Cancer Cell Lines And In In Vivo Patient-Derived Xenograft Model 
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 
BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15 
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026 
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - 12 Health Care Stocks Moving In Wednesday's After-Market Session
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on BLRX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alyeska Investment Group, L.p. | 1.08% | 866,495 | 202.24K | Sep 29, 2024 |
| CVI Holdings, LLC | 1.02% | 815,683 | 190.38K | Jun 29, 2024 |
| Envestnet Asset Management | 0.30% | 239,186 | 55.83K | Sep 29, 2024 |
| Values First Advisors, Inc. | 0.25% | 197,516 | 46.10K | Sep 29, 2024 |
| Morgan Stanley | 0.25% | 197,537 | 46.10K | Sep 29, 2024 |
| Atria Investments, Inc. | 0.17% | 133,974 | 31.27K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 39,993 | 9.33K | Oct 30, 2024 |